Wolf G T, Peterson K A, Lovett E J
Otolaryngology Service, Veterans Administration Medical Center, Ann Arbor, MI 48105.
Head Neck Surg. 1985 May-Jun;7(5):350-6. doi: 10.1002/hed.2890070503.
To determine if patients with head and neck squamous cell carcinoma represent an appropriate population for immune reconstitution with thymosin alpha 1, leukocyte migration inhibition (LMI) in response to phytohemagglutinin was measured in 24 previously untreated patients with head and neck cancer, and the in vitro effects of thymosin alpha 1 on migration inhibition were assessed. Compared to normal subjects, LMI was impaired in the head and neck cancer patients. Thymosin alpha 1, in vitro, was associated with improvement in LMI in the cancer patients. Improvements in migration response with thymosin alpha 1 appeared to be independent of levels of various T-lymphocyte subpopulations. However, patients with a normal LMI response had lower suppressor/cytotoxic cell levels than normal subjects or patients with impaired LMI. The findings confirm prior reports of the effects of thymic hormones on lymphokine production in vitro and provide rationale for further clinical studies of thymosin alpha 1 in patients with head and neck squamous cell carcinoma.
为了确定头颈部鳞状细胞癌患者是否是使用胸腺肽α1进行免疫重建的合适人群，对24例未经治疗的头颈部癌症患者进行了植物血凝素诱导的白细胞迁移抑制（LMI）检测，并评估了胸腺肽α1对迁移抑制的体外作用。与正常受试者相比，头颈部癌症患者的LMI受损。体外实验中，胸腺肽α1可使癌症患者的LMI得到改善。胸腺肽α1引起的迁移反应改善似乎与各种T淋巴细胞亚群的水平无关。然而，LMI反应正常的患者其抑制/细胞毒性细胞水平低于正常受试者或LMI受损的患者。这些发现证实了先前关于胸腺激素对体外淋巴因子产生影响的报道，并为进一步对头颈部鳞状细胞癌患者进行胸腺肽α1的临床研究提供了理论依据。
